FDA Approves Brepocitinib for Dermatomyositis

The FDA approved brepocitinib as the first targeted oral treatment specifically indicated for dermatomyositis, based on positive phase 3 VALOR trial results showing significant efficacy and safety compared to placebo. The drug addresses a longstanding unmet need in managing this rare autoimmune disease by providing a non-steroidal alternative to corticosteroids and off-label immunosuppressants.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.